|
1
|
American Cancer Society: Cancer Facts
& Figures. American Cancer Society. Atlanta, GA: 2014.
|
|
2
|
Malvezzi M, Bertuccio P, Levi F, La
Vecchia C and Negri E: European cancer mortality predictions for
the year 2013. Ann Oncol. 24:792–800. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neoptolemos JP, Dunn JA, Stocken D, Almond
J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, et
al: Adjuvant chemoradiotherapy and chemotherapy in resectable
pancreatic cancer: A randomised controlled trial. Lancet.
358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adsay NV, Basturk O, Cheng JD and Andea
AA: Ductal neoplasia of the pancreas: nosologic, clinicopathologic,
and biologic aspects. Semin Radiat Oncol. 15:254–264. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bilimoria KY, Bentrem DJ, Ko CY, Stewart
AK, Winchester DP and Talamonti MS: National failure to operate on
early stage pancreatic cancer. Ann Surg. 246:173–180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Hoff DD, Ervin T, Arena FP, et al:
Increased survival in pancreatic cancer with nab-paclitaxel plus
gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET, et al: Toxicity and response criteria of the
Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrone CR, Finkelstein DM, Thayer SP,
Muzikansky A, Fernandez-delCastillo C and Warshaw AL: Perioperative
CA19-9 levels can predict stage and survival in patients with
resectable pancreatic adenocarcinoma. J Clin Oncol. 24:2897–2902.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
Hoboken, NJ, USA: 3241–3244. 2009.
|
|
11
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2009. View Article : Google Scholar
|
|
12
|
Borad MJ, Saadati H, Lakshmipathy A,
Campbell E, Hopper P, Jameson G, Von Hoff DD and Saif MW: Skeletal
metastases in pancreatic cancer: A retrospective study and review
of the literature. Yale J Biol Med. 82:1–6. 2009.PubMed/NCBI
|
|
13
|
Burris HA 3rd, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, et al: Improvements in survival and
clinical benefit with gencitabine as first-line therapy for
patients with advanced pancreas cancer: A randomized trial. J Clin
Oncol. 15:2403–2413. 2007.
|
|
14
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Buccheri G, Ferrigno D and Tamburini M:
Karnofsky and ECOG performance status scoring in lung cancer: A
prospective, longitudinal study of 536 patients from a single
institution. Eur J Cancer. 32A:1135–1141. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shakir AR: A Near-Complete response to
treatment with gemcitabine plus nab (®)-Paclitaxel in a
patient with metastatic pancreatic cancer and poor performance
status: A case report. Case Rep Oncol. 7:711–717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guillen-Ponce C, López R, Macarulla T,
Rivera F, Cubillo A, Carrato A, et al: A phase I/II trial to
evaluate the efficacy and safety of nab-paclitaxel in combination
with gemcitabine for the treatment of frail patients with advanced
or metastatic pancreatic cancer: Safety results of the Phase I
trial. Ann Oncol. 25(suppl 4): iv2382014.
|
